Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Therap Adv Gastroenterol
Autors principals: Massimi, Davide, Barberio, Brigida, Bertani, Lorenzo, Costa, Francesco, Ferronato, Antonio, Facchin, Sonia, Cardin, Romilda, Cingolani, Linda, Casadei, Cesare, D’Incà, Renata, Zingone, Fabiana, Savarino, Edoardo Vincenzo
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239954/
https://ncbi.nlm.nih.gov/pubmed/34249147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211023384
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars